April 26, 2016
Clearside Biomedical, Inc. Announces Positive Preliminary Phase 2 Results in Patients with Macular Edema Associated with Retinal Vein Occlusion
Alpharetta, GA (April 26, 2016) – Clearside Biomedical, Inc. today announced that its Phase 2 clinical trial evaluating concomitant administration of suprachoroidal ZUPRATA™, Clearside’s proprietary form of triamcinolone acetonide, together with intravitreal aflibercept (EYLEA®), for the treatment of macular edema associated with retinal vein occlusion (RVO), achieved its primary endpoint.
April 25, 2016
Hatteras Venture Partners Earns CEO Cancer Gold Standard Accreditation
CARY, N.C.–(BUSINESS WIRE)–The CEO Roundtable on Cancer has accredited Hatteras Venture Partners, an early-stage venture capital investment company in Durham, N.C., with the CEO Cancer Gold StandardTM recognizing its efforts to reduce the risk of cancer for its employees and covered family members.
March 24, 2016
Bivarus Raises $2 Million to Fuel Expansion Following Strong Growth in 2015
DURHAM, N.C. (Business Wire) March 23, 2016 – Bivarus, a patient-centered analytics company working with healthcare organizations to measure and analyze the patient experience, announced today it raised $2 million in its oversubscribed round of funding. This latest financing was co-led by new investor Hatteras Venture Partners and existing investor Excelerate Health Ventures.
March 7, 2016
TBJ names 2016 Women in Business Lifetime Achievement Award winner
Each year as a part of its annual Women In Business Awards, Triangle Business Journal selects a female executive who has impacted the Triangle community not only with the work she’s accomplished throughout her career, but also her dedication to the community’s greater good. We call it the Lifetime Achievement Award.
March 2, 2016
Carolina Research Ventures Selects Hatteras as Manager of Investments
March 2, 2016 – Chapel Hill and Durham, NC – Hatteras Venture Partners and Carolina Research Ventures, LLC (CRV) announced today the selection of Hatteras as the manager of CRV’s investment fund. CRV is an early stage venture investment fund created to support companies sourced at the University of North Carolina at Chapel Hill.
March 2, 2016
Medfusion Announces Latest Version of Medfusion Plus at HIMSS16
CARY, N.C.–(BUSINESS WIRE)–Medfusion, a leading provider of patient experience management (PXM) solutions, today announced it will debut the latest version of its mobile app, Medfusion Plus, at the Healthcare Information and Management Systems Society 2016 Annual Conference & Exhibition (HIMSS16). This latest product development supports the company’s initiative to empower patients by facilitating access to and transparency of their own health data through mobile devices.
February 5, 2016
Improving Odds for Women in Tech? Take Notes from Biotech
At our entrepreneurial support organization, the Council for Entrepreneurial Development (CED), we often joke about adhering to the proper dress and catering code for our networking events: jeans and beer for tech; suits, wine and cocktails for life sciences.
January 8, 2016
Clearside Biomedical, Inc. Announces Positive Topline Data from Phase 2 Clinical Trial for the Treatment of Macular Edema Associated with Non-Infectious Uveitis
ALPHARETTA, Ga.–(BUSINESS WIRE)–Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye, today announced positive results from the company’s Phase 2 clinical trial of CLS-TA, Clearside’s proprietary form of triamcinolone acetonide, using suprachoroidal space (SCS™) drug administration for the treatment of macular edema associated with non-infectious uveitis.